Tech Company Financing Transactions
ViaCyte Funding Round
On 7/10/2013, ViaCyte announced $10.6 million in Series C funding from Asset Management Ventures, Johnson & Johnson Development Corporation and Sanderling Ventures.
Transaction Overview
Company Name
Announced On
7/10/2013
Transaction Type
Venture Equity
Amount
$10,600,000
Round
Series C
Investors
Proceeds Purpose
The Company will use the funds to pursue clinical development of VC-01. VC-01 is a development-stage product that consists of pancreatic precursor cells (designated PEC-01) manufactured through directed differentiation of stem cells sourced from a proprietary human embryonic stem cell line, and encapsulated in a proprietary, immune protective medical device (the ENCAPTRA device).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3550 General Atomics Ct.
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
ViaCyte is a preclinical therapeutic company focused on diabetes. Our therapy is based on pancreatic beta cell progenitors (Pro-Islet) derived from human pluripotent stem cells. These cells are implanted using a durable and retrievable encapsulation device.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 7/10/2013: SynapSense venture capital transaction
Next: 7/10/2013: 7signal venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs